Adherex Teams Up With Scynexis

Adherex Technologies said that it will employ the services of another Triangle drug company, Scynexis, as it tries to develop a way to administer drugs orally. Adherex's lead biotechnology compound, ADH-1, is administered by intravenous injection. While intravenous injection is the appropriate delivery method for that type of anticancer drug, Adherex wants to expand its delivery options for its other potential drug candidates.

Triangle Business Journal (http://www.bizjournals.com/triangle/stories/2005/03/21/daily17.html)